PCSK9抑制剂对动脉粥样硬化性脑梗死患者血脂水平影响的临床研究  

Effect of PCSK9 inhibitors on blood lipid level in patients with atherosclerotic cerebral infarction

作　　者：魏茂群 李庭毅 WEI Maoqun;LI Tingyi(Postgraduate Training Base of Jinzhou Medical University(Xiaogan Central Hospital),Xiaogan,Hubei 432000,China)

机构地区：[1]锦州医科大学研究生培养基地(孝感市中心医院),湖北孝感432000

出　　处：《中国医学工程》2023年第7期18-22,共5页China Medical Engineering

摘　　要：目的观察前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂对动脉粥样硬化性脑梗死(ASCI)患者血脂水平及预后的影响。方法将2021年1月至2021年12月于湖北孝感市中心医院收治的100例符合纳入标准的ASCI患者随机分为对照组和试验组,每组各50例。对照组予以阿托伐他汀钙片治疗,试验组予以阿托伐他汀钙片+PCSK9抑制剂(瑞百安)治疗,药物干预周期为6个月。比较两组受试者用药前后血清PCSK9浓度、血脂水平、同型半胱氨酸(Hcy)及颈动脉内中膜厚度(IMT)等卒中危险因素,分析血清PCSK9水平与ASCI常见危险因素的相关性。结果PCSK9抑制剂在阿托伐他汀钙片治疗的基础上可以显著降低ASCI患者血清PCSK9水平和血清低密度脂蛋白胆固醇(LDL-C)水平(P<0.05);与对照组相比,试验组IMT显著降低(P<0.05);试验组血清PCSK9水平与血清LDL-C显著相关。结论PCSK9抑制剂作为新型降脂药物在阿托伐他汀钙片治疗的基础上可以降低受试者的LDL-C水平,改善患者的预后,降低动脉硬化性脑梗死的发生率。【Objective】To observe the effect of proprotein convertase subtilisin-kexin type 9(PCSK9)inhibitors on blood lipid level and prognosis in patients with atherosclerotic cerebral infarction(ASCI).【Methods】A total of 100 ASCI patients who met the inclusion criteria were randomly divided into a control group and an experimental group,with 50 cases in each group.The control group was treated with atorvastatin calcium tablets,while the experimental group was treated with atorvastatin calcium tablets and PCSK9 inhibitor(Repatha).The drug intervention period was 6 months.The serum PCSK9 concentration,blood lipid levels,homocysteine(Hcy),carotid intima-media thickness(IMT),and other risk factors of stroke were compared between the two groups before and after treatment,and the correlation between serum PCSK9 level and common risk factors of atherosclerotic cerebral infarction was analyzed.【Results】Based on atorvastatin calcium tablet treatment,PCSK9 inhibitor could significantly reduce serum PCSK9 level and serum low-density lipoprotein cholesterol(LDL-C)level in ASCI patients(P<0.05).Compared with the control group,the IMT of the experimental group was significantly decreased(P<0.05).Serum PCSK9 level was significantly correlated with serum LDL-C.【Conclusion】As a new lipid-lowering drug,PCSK9 inhibitor can reduce the LDL-C level,improve the prognosis of patients and reduce the incidence of atherosclerotic cerebral infarction based on atorvastatin calcium tablets.

关 键 词：前蛋白转化酶枯草溶菌素9抑制剂 动脉粥样硬化 脑梗死 低密度脂蛋白胆固醇 

分 类 号：R743.1[医药卫生—神经病学与精神病学]